Class information for:
Level 1: TRASTUZUMAB//LAPATINIB//PERTUZUMAB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3276 1944 43.1 83%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TRASTUZUMAB Author keyword 289 37% 32% 621
2 LAPATINIB Author keyword 142 46% 12% 231
3 PERTUZUMAB Author keyword 87 65% 4% 83
4 HER 2 Author keyword 46 12% 18% 355
5 HER2 POSITIVE Author keyword 37 53% 3% 50
6 DUAL TYROSINE KINASE INHIBITOR Author keyword 27 92% 1% 11
7 NERATINIB Author keyword 20 63% 1% 20
8 METASTATIC BREAST CANCER Author keyword 16 10% 8% 146
9 TRASTUZUMAB RESISTANCE Author keyword 16 48% 1% 24
10 GW572016 Author keyword 15 82% 0% 9

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 TRASTUZUMAB 289 37% 32% 621 Search TRASTUZUMAB Search TRASTUZUMAB
2 LAPATINIB 142 46% 12% 231 Search LAPATINIB Search LAPATINIB
3 PERTUZUMAB 87 65% 4% 83 Search PERTUZUMAB Search PERTUZUMAB
4 HER 2 46 12% 18% 355 Search HER+2 Search HER+2
5 HER2 POSITIVE 37 53% 3% 50 Search HER2+POSITIVE Search HER2+POSITIVE
6 DUAL TYROSINE KINASE INHIBITOR 27 92% 1% 11 Search DUAL+TYROSINE+KINASE+INHIBITOR Search DUAL+TYROSINE+KINASE+INHIBITOR
7 NERATINIB 20 63% 1% 20 Search NERATINIB Search NERATINIB
8 METASTATIC BREAST CANCER 16 10% 8% 146 Search METASTATIC+BREAST+CANCER Search METASTATIC+BREAST+CANCER
9 TRASTUZUMAB RESISTANCE 16 48% 1% 24 Search TRASTUZUMAB+RESISTANCE Search TRASTUZUMAB+RESISTANCE
10 GW572016 15 82% 0% 9 Search GW572016 Search GW572016

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TRASTUZUMAB 65 16% 19% 373
2 HERCEPTIN 61 47% 5% 97
3 DIMERIZATION INHIBITOR 56 69% 2% 48
4 NSABP B 31 45 83% 1% 25
5 HER 2 45 18% 12% 225
6 TRASTUZUMAB RESISTANCE 44 33% 6% 110
7 GW572016 43 53% 3% 58
8 RHUMAB 2C4 41 100% 1% 15
9 LAPATINIB 41 32% 6% 107
10 PLUS TRASTUZUMAB 39 63% 2% 40

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
HER2-directed therapy: current treatment options for HER2-positive breast cancer 2015 5 82 66%
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice 2007 798 70 47%
Treatment of HER2-positive breast cancer: current status and future perspectives 2012 195 125 56%
A systematic review of dual targeting in HER2-positive breast cancer 2014 21 41 59%
Targeting HER2 for the Treatment of Breast Cancer 2015 3 82 70%
Treatment of HER2-positive breast cancer 2014 14 81 60%
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors 2013 35 76 67%
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer 2009 175 83 54%
Resistance to human epidermal growth factor receptor type 2-targeted therapies 2014 8 75 71%
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development 2014 8 50 68%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 MED DEV ONCOL 6 58% 0.4% 7
2 ONCOL MED DEV 5 44% 0.4% 8
3 ARIZONA ONCOL 4 75% 0.2% 3
4 EDINBURGH BREAKTHROUGH UNIT 3 39% 0.4% 7
5 BREAST DATA 2 23% 0.5% 9
6 ANAT PATOL BIOREN 2 67% 0.1% 2
7 KLIN PHARM DIAGNOST 2 67% 0.1% 2
8 N COPERNICUS MEM HOSP 2 67% 0.1% 2
9 VANDERBILT INGRAM COMPREHENS CANC CANC B 2 67% 0.1% 2
10 THER EUT INNOVAT ONCOL HAEMATOL 2 50% 0.2% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000225128 HER 2//HER2 TESTING//POLYSOMY 17
2 0.0000206274 HER3//NUCLEAR EGFR//EGFR FAMILY
3 0.0000179753 C ERBB 2//HER 2 NEU//P185
4 0.0000126071 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
5 0.0000117040 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY
6 0.0000116333 ANTIBODY DRUG CONJUGATE//ANTIBODY DRUG CONJUGATES//T DM1
7 0.0000089834 METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL
8 0.0000087781 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
9 0.0000085969 INFLAMMATORY BREAST CANCER//NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER
10 0.0000072626 ONCOTYPE DX//TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE